A Proof-of-concept Phase II Study to Evaluate Efficacy, Safety and Pharmacokinetics of 4SC-201 and the Treatment Combination of Sorafenib Plus 4SC-201 in Patients With Hepatocellular Carcinoma Exhibiting Progressive Disease Under Sorafenib Treatment.

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 28 May 2019

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Resminostat (Primary) ; Sorafenib
Indications Liver cancer
Focus Pharmacokinetics; Proof of concept; Therapeutic Use
Acronyms SHELTER
Sponsors 4SC

Most Recent Events

02 Dec 2016 Results of biomarker analysis from SHELTER,SAPHIRE and SHORE trials presented at the 28th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics.
10 Nov 2016 According to a 4SC media release, full data set of this trial will be presented at an upcoming scientific conference.
06 May 2014 Results published in an 4SC media release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight